PMID- 19385978
OWN - NLM
STAT- MEDLINE
DCOM- 20090916
LR  - 20220331
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
VI  - 11 Suppl 2
DP  - 2009 May
TI  - Metformin--the gold standard in type 2 diabetes: what does the evidence tell us?
PG  - 3-8
LID - 10.1111/j.1463-1326.2008.01031.x [doi]
AB  - Metformin is a cornerstone of oral antidiabetic treatment. Recent joint American 
      and European guidelines recommend instituting metformin therapy along with 
      lifestyle modification at the time type 2 diabetes mellitus (T2DM) is diagnosed. 
      Metformin acts to reduce hepatic gluconeogenesis and improve glucose uptake, and 
      it may exert protective effects on pancreatic islet cells. Although metformin 
      therapy produces substantial reductions in HbA1c, it does not produce body weight 
      gain, is not associated with substantial risk for hypoglycaemia and has neutral 
      to positive effects on lipids and blood pressure. The major adverse events 
      associated with metformin are gastrointestinal. T2DM progresses even with 
      initially effective monotherapy, and most patients will therefore receive 
      combination therapy. When selecting agents to coadminister with metformin, a 
      physician must consider efficacy in glycaemic control, safety, tolerability and 
      any effects that may compromise overall efficacy (e.g. effects on body weight, 
      lipids or blood pressure). In this regard, incretin-based therapies have 
      characteristics that make them particularly suitable for add-on therapy with 
      metformin.
FAU - Bosi, E
AU  - Bosi E
AD  - Department of Medicine, Diabetes and Endocrinology Unit, San Raffaele Scientific 
      Institute and Vita-Salute San Raffaele University, Milan, Italy. 
      bosi.emanuele@hsr.it
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Hypoglycemic Agents)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Body Weight/drug effects
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Evidence-Based Medicine
MH  - Humans
MH  - Hypoglycemic Agents/adverse effects/pharmacology/*therapeutic use
MH  - Metformin/adverse effects/pharmacology/*therapeutic use
MH  - Treatment Outcome
RF  - 18
EDAT- 2009/04/24 09:00
MHDA- 2009/09/17 06:00
CRDT- 2009/04/24 09:00
PHST- 2009/04/24 09:00 [entrez]
PHST- 2009/04/24 09:00 [pubmed]
PHST- 2009/09/17 06:00 [medline]
AID - DOM1031 [pii]
AID - 10.1111/j.1463-1326.2008.01031.x [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2009 May;11 Suppl 2:3-8. doi: 
      10.1111/j.1463-1326.2008.01031.x.